At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome
In Brief
A Phase 4 clinical trial evaluating 3 months dual anti-platelet therapy and 12 months dual anti-platelet therapy for Acute Coronary Syndrome and Coronary Artery Disease. Completed, enrolled 5,094 participants across 1 site.
Detailed Summary
Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Recent evidence suggests that shorter durations of dual anti-platelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations. We here propose an international randomised controlled trial of 18,318 patients with type 1 myocardial infarction allocated to differing durations of dual anti-platelet therapy. We will use electronic health record linkage to track duration of therapy and clinical outcomes in a real-world, real-time, efficient and highly cost-effective trial. This has the potential to define treatment duration, settle a major outstanding international controversy, and influence modern cardiology practice across the world.
Study Details
Timeline
Interventions
Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.